Globus Medical, Inc. $GMED Shares Acquired by Bridge City Capital LLC

Key Points

• Bridge City Capital increased its Globus Medical position by 20.5% in the third quarter, bringing its holdings to 114,433 shares valued at approximately $8.6 million. Institutional investors collectively own 95.16% of GMED.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $99.46, despite several recent target-price reductions.
• Globus Medical reported quarterly EPS of $1.34, exceeding estimates of $1.10, while revenue rose 5.9% year over year to $789.61 million. However, two directors recently sold a combined 55,000 shares, and the stock was trading near $77.98.

Bridge City Capital LLC grew its position in Globus Medical, Inc. (NYSE:GMED - Free Report) by 20.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 114,433 shares of the medical device company's stock after buying an additional 19,494 shares during the quarter. Globus Medical accounts for approximately 1.8% of Bridge City Capital LLC's holdings, making the stock its 13th biggest holding. Bridge City Capital LLC owned 0.09% of Globus Medical worth $8,571,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Globus Medical by 10.4% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,485 shares of the medical device company's stock valued at $486,000 after acquiring an additional 610 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Globus Medical during the third quarter worth about $1,169,000. Vise Technologies Inc. raised its position in shares of Globus Medical by 8.7% in the 3rd quarter. Vise Technologies Inc. now owns 14,814 shares of the medical device company's stock worth $1,110,000 after acquiring an additional 1,182 shares in the last quarter. State of Wyoming increased its position in shares of Globus Medical by 52.6% during the 3rd quarter. State of Wyoming now owns 10,670 shares of the medical device company's stock valued at $799,000 after purchasing an additional 3,679 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al boosted its position in shares of Globus Medical by 51.0% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 35,510 shares of the medical device company's stock valued at $2,660,000 after acquiring an additional 12,000 shares during the last quarter. Institutional investors own 95.16% of the company's stock.

Analyst Ratings Changes

GMED has been the topic of several research analyst reports. BTIG Research reiterated a "neutral" rating on shares of Globus Medical in a research note on Friday, September 18th. Truist Financial decreased their price objective on shares of Globus Medical from $115.00 to $100.00 and set a "buy" rating on the stock in a research report on Thursday, July 16th. Wells Fargo & Company cut their target price on Globus Medical from $103.00 to $99.00 and set an "overweight" rating on the stock in a research report on Friday, August 7th. Royal Bank Of Canada dropped their target price on Globus Medical from $115.00 to $85.00 and set an "outperform" rating on the stock in a research report on Thursday, October 1st. Finally, Weiss Ratings reiterated a "hold (c+)" rating on shares of Globus Medical in a research report on Friday, October 9th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, Globus Medical presently has a consensus rating of "Moderate Buy" and a consensus target price of $99.46.

Key Stories Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research raised EPS estimates across multiple periods, including Q3 2026 to $1.19, FY2026 to $4.98, FY2027 to $5.07, and FY2028 to $5.89. The firm also lifted estimates for Q1 2027, Q2 2027 and Q2 2028 by $0.01 each and maintained a “Strong-Buy” rating. The revisions suggest modestly improving expectations for Globus Medical’s earnings outlook. MarketBeat Globus Medical analyst estimates
• Positive Sentiment: Globus Medical was highlighted as a healthcare technology stock positioned for digital-health growth. Zacks cited projected 2026 earnings growth, an attractive valuation and innovation in essential medical services as reasons the company could benefit from broader healthcare technology adoption. Zacks healthcare technology stocks article
• Positive Sentiment: Another analysis called GMED undervalued even after a 77% run. This supports the view that analysts see additional upside based on Globus Medical’s earnings prospects and valuation, although the large prior gain may also encourage profit-taking. Globus Medical stock looks undervalued article
• Neutral Sentiment: The estimate increases were small—generally just $0.01 per share—and Zacks’ FY2026 estimate of $4.98 remains slightly below the broader consensus of $4.99. As a result, the revisions provide incremental support but may not be strong enough to overcome near-term selling pressure.
• Negative Sentiment: With GMED having already advanced substantially, investors may be locking in gains while waiting for a larger earnings or guidance catalyst. This profit-taking dynamic appears to be outweighing the otherwise favorable analyst commentary today.

Insider Buying and Selling

In other news, Director James Tobin sold 30,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $74.58, for a total value of $2,237,400.00. Following the transaction, the director owned 15,000 shares in the company, valued at approximately $1,118,700. This trade represents a 66.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Stephen T. Zarrilli sold 25,000 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the transaction, the director directly owned 25,000 shares of the company's stock, valued at $2,176,000. This trade represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 18.38% of the company's stock.

Globus Medical Trading Down 0.1%

NYSE:GMED opened at $77.98 on Monday. The business's 50-day moving average is $77.64 and its 200 day moving average is $83.51. Globus Medical, Inc. has a 12 month low of $59.51 and a 12 month high of $101.40. The company has a market capitalization of $10.47 billion, a P/E ratio of 19.94, a P/E/G ratio of 1.26 and a beta of 0.96.

Globus Medical (NYSE:GMED - Get Free Report) last announced its earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.24. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The company had revenue of $789.61 million for the quarter, compared to analysts' expectations of $782.88 million. During the same quarter in the previous year, the company posted $0.86 EPS. The firm's quarterly revenue was up 5.9% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, research analysts forecast that Globus Medical, Inc. will post 4.99 earnings per share for the current year.

Globus Medical Profile

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.